Jumawan, Julie D.
HRN: 22-27-78 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/06/2023
CEFAZOLIN 1GM (VIAL)
02/06/2023
02/13/2023
IV
1g
Q8hrs
Giant Cell Tumor Distal 3rd Femur Right
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes